Quidel
In the wake of suspending guidance to review the business in the first quarter of the year, QuidelOrtho has restructured and resumed offering a financial outlook.
QuidelOrtho Withdraws Submitted Savanna Respiratory Panel, Obtains FDA Clearance for COVID-19 Test
The firm said the final performance data for the Savanna RVP4+ panel did not meet its expectations, and it will now resubmit a next-gen version.
The firm discussed further reducing its headcount as well as increasing its molecular and lab instrument menu as a path to margin restoration.
UBS Downgrades QuidelOrtho to Sell
The investment bank cited risks in the firm's guidance for respiratory test sales and in the launch of the Savanna point-of-care MDx system.
QuidelOrtho Parts Ways With Longtime CEO Doug Bryant
Bryant will be replaced by an "Office of the CEO" consisting of interim CEO Michael Iskra, President Robert Bujarski, and others.
Jan 16, 2024
Aug 9, 2023
QuidelOrtho Revenues up 8 Percent in Q2
Oct 12, 2022
QuidelOrtho Reports Preliminary Q3 Revenues
Aug 18, 2022
QuidelOrtho Board Authorizes $300M Share Repurchase
Aug 5, 2022
QuidelOrtho Q2 Revenues Rise 34 Percent
Apr 8, 2022
Quidel Expects up to $1B in Q1 Revenues
Feb 17, 2022